

# Quarterly Financial Statements Q1-2022 of the TELES Group

(IFRS, unaudited)

## Key figures from 1 January 2022 to 31 March 2022

- Sales Q1-2022 of EUR 19.5 million (previous year: EUR 540 thousand, >> 500 %)
- Operating cash flow Q1-2022 of EUR 2.2 million (previous year EUR 125 thousand, >> 500 %)

Overview of the corporate key figures of TELES Group for Q1-2022 (in accordance with IFRS, unaudited)

TELES Group	01.01.2021 -	01.01.2022 -	Change
in thousand Euro	31.03.2021	31.03.2022	
Sales revenues	540	19.503	> +500%
Cost of materials	121	18.155	> +500%
Personnel expenses	373	822	121%
Gross profit	105	394	277%
Operating result/EBIT	-102	85	184%
EBITDA	-58	180	412%
Group result	-109	-51	53%



### **Interim Management Report**

With the Pharma expansion field, TELES opened a new segment at the end of 2021, in which, as in telecommunications software, the management of enormous amounts of data and the digitization of business processes lead to growth spurts.

The earnings situation of the TELES Group improved significantly in the first quarter of 2022 compared to the same period of the previous year. The reason for this is the inclusion of EURO RX Arzneimittel GmbH in the consolidated financial statements since January 2022. The TELES Group achieved sales revenues of EUR 19.5 million (previous year: EUR 540 thousand). The gross profit increased accordingly to EUR 1.3 million (previous year: EUR 419 thousand).

Personnel expenses increased by 121% to EUR 822 thousand (previous year: EUR 373 thousand). Depreciation amounted to EUR 95k (prior year: EUR 22 thousand). Other operating income was EUR 49 thousand (previous year: EUR 0 thousand). With the increase in other operating expenses of TER 444 (previous year: 142), the EBITDA was EUR 180 thousand (previous year: -58 thousand) and the consolidated result at EUR - 51 thousand (previous year: EUR -109 thousand).

The balance sheet total of TELES increased by EUR 11.3 million compared to the previous year. This is due to the increase in current assets by EUR 11.4 million.

In the cash flow statement, the operating cash flow is EUR 2.2 million (previous year: EUR 125 thousand). The investment activity of EUR 383 thousand is primarily characterized by investments in fixed assets for EURO RX Arzneimittel GmbH. As of March 31, 2021, the financial resources were EUR 3,1 million (previous year TER 798).



## **Risk Report**

In the management report for the past 2021 fiscal year, all relevant risks known to us were listed conscientiously. Nothing to add now. We ensure the company's liquidity through very conscientious planning. We continue to monitor incoming payments very closely and thus counteract payment defaults on the part of customers. Whether the sales and earnings targets will be achieved depends – apart from internal company factors – to a significant extent on economic, political and industry-specific developments – particularly in our core market of Europe.

### Forecast

For the current fiscal year, we expect sales of EUR 55 to 65 million and a positive result (EBIT) of EUR 300 to 500 thousand for the TELES Group.

TELES AG Informationstechnologien Oliver Olbrich Chief Executive Officer May 2022



## **Interim Financial Statements**

## Consolidated Balance Sheet (IFRS, unaudited)

in thousand Euro		31.12.2021	31.03.2022
Assets			
Α.	Fixed assets		
١.	Intangible assets	0	38
II.	Tangible assets	250	1.519
.	Financial assets	1.894	542
Total fixed assets		2.144	2.100
В.	Current assets		
I.	Stocks	5	4.409
II.	Debtors and other assets	351	3.305
III.	Cheque, Cash at bank and in hand	391	3.066
Total current assets		842	12.206
Prepayments and accrued income 48		75	
Total assets		3.034	14.381

Page 4 of 9



in tl	housand Euro	31.12.2021	31.03.2022
_			
	iity and liabilities		
Α.	Equity		
١.	Ordinary shares	6.233	6.233
11.	Capital reserve	242	242
III.	Revenue reserves		
	Loss carried forward	-4.906	-4.906
	Profit or loss for the period	0	-52
Total equity		1.569	1.517
В.	Minority interest	0	365
C.	Provisions		
١.	Tax provisions	625	1.033
II.	Other provisions	156	237
Total provisions		780	1.270
D.	Creditors		
١.	Financial liabilities	0	8.364
II.	Payment received on account	58	22
111.	Trade creditors	210	1.462
IV.	Liabilities to affiliated companies	0	0
V.	Other creditors	288	1.047
Total creditors		556	10.896
E.	Deferred income	129	329
F.	Deferred taxes	0	4
Total equity and liabilities3.03414.38			14.381



TEL	ES Group	01.01.2021 -	01.01.2022 -
in thousand Euro		31.03.2021	31.03.2022
1.	Sales revenues	540	19.503
2.	Cost of materials	121	18.155
3.	Gross profit	419	1.348
4.	Personnel expenses	373	822
5.	Depreciation	44	95
6.	Other income	0	49
7.	Other expenses	105	394
8.	Operating result/EBIT	-102	85
9.	Other interest receivable and similar income	0	0
10.	Interest payable and similar charges	6	54
11.	Financial income	-109	31
12.	Taxes on income	0	82
13.	Profit or loss after taxes	-109	-51
14.	Other taxes	0	0
15.	Group result	-109	-51
	result to be allocated to TELES shareholders	-109	-110
	result to be allocated to minorities interest	0	59
Result per share (in EURO)-0,0025-0,			-0,0008

## Consolidated Statement of income (IFRS, unaudited)



## Statement of comprehensive income (IFRS, unaudited)

	Nominal value of the shares EUR	Capital reserve EUR	Revenue reserves EUR	<b>Total Equity</b> EUR
December 31, 2020	4.369.626	284.206	-4.661.177	-7.345
Capital increase	0	0	0	0
Net profit/loss for the period	0	0	-108.514	-108.514
March 31, 2021	4.369.626	284.206	-4.769.691	-115.859
December 31, 2021	6.233.418	241.551	-4.905.846	1.569.123
Capital increase	0	0	0	0
Net profit/loss for the period	0	0	-51.657	-51.657
March 31, 2022	6.233.418	241.551	-4.957.503	1.517.465



## Development of the consolidated cash flow statement (IFRS, unaudited)

TELES Group		01.01.2021 -	01.01.2022 -
in EUR		31.03.2021	31.03.2022
Casl	n flow from operating activities		
	Net profit/loss for the financial year	-108.514	-51.657
+	Depreciation	44.245	94.975
+/-	Changes to provisions	-5.693	-181.457
-/+	Other Non-cash expenses and income	0	-173.290
-/+	Changes to Stocks and Trade Receivables	10.009	1.862.227
+/-	Changes to Trade Payables and Other liabilities	178.312	499.565
+	Interest expenses	6.363	54.384
-	interest income	0	283
+/-	Income-tax expense/income	0	82.339
		124.722	2.187.368
Casl	n flow from investing activities		
-	Investments in fixed assets	-78.287	-383.844
		-78.287	-383.844
Net change in cash and cash equivalents		46.435	1.803.524
+	Cash and cash equivalents at beginning of period	751.552	1.262.490
Cash and cash equivalents at end of period		797.987	3.066.014



## Summary of Significant Financial Reporting Policies and Standards

#### **Presentation Basis**

The annual financial statements of TELES as of December 31, 2021, were prepared in accordance with the commercial law regulations for large corporations within the meaning of Section 267 (3) sentence 2 HGB and in compliance with the special provisions of the German Stock Corporation Act. The total cost method is used for the income statement.

The interim report as of March 31, 2022, was prepared based on the International Accounting Standard (IAS) 34 "Interim Reporting".

All IAS and IFRS binding as of March 31, 2022, as well as interpretations of the International Financial Reporting Interpretations Committee (IFRIC), formerly the Standing Interpretations Committee (SIC), have been applied.

#### Audit Review

The interim financial statements and the interim management report were neither audited nor reviewed by the auditor.

#### Responsibility Statement by the Company Officers (Management)

To the best of our knowledge, we assure you that, in accordance with the applicable accounting principles for interim reporting, the interim consolidated financial statements give a true and fair view of the group's net assets, financial position and results of operations, and the interim group management report gives a true picture of the course of business including the business result and the position of the group are presented in such a way that a picture is given that corresponds to the actual circumstances, and the main opportunities and risks of the probable development of the group in the remaining financial year are described.

Page 9 of 9